Avantor Inc is a global supplier of ultra-pure materials and integrated solutions for the life sciences and advanced technology sectors
The company supports a wide range of industries by providing high-quality products, including chemicals, reagents, and consumables, as well as laboratory services and customized solutions. Avantor's extensive portfolio is designed to enhance research and development, manufacturing processes, and quality control, helping customers accelerate innovation and improve outcomes across various applications, from pharmaceuticals to biotechnology and diagnostics. Its commitment to sustainability and operational excellence drives the company's mission to enhance scientific discovery and guide advancements in the scientific community.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Danaher (NYSEDHR) and the best and worst performers in the research tools & consumables industry.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Revvity (NYSERVTY) and the best and worst performers in the research tools & consumables industry.
Repligen reported Q4 EPS of $0.44, beating estimates, with revenue of $167.55 million. The company projects 2025 sales of up to $710 million as the market recovers.
Shares of life sciences company Avantor (NYSEAVTR)
fell 9.4% in the afternoon session after the company reported weak fourth quarter results. Its revenue missed and its organic revenue fell slightly short of Wall Street's estimates. Despite the return to organic growth and margin improvements enabling the company to beat analysts' EBITDA and earnings estimates, markets seem unimpressed. The top line miss indicates the bar set for the company is high, and as the company recovers from weaknesses in some end markets, it remains to be seen if the turnaround will continue. Overall, this was a weaker quarter.
Life sciences company Avantor (NYSEAVTR) fell short of the market’s revenue expectations in Q4 CY2024, with sales falling 2.1% year on year to $1.69 billion. Its non-GAAP profit of $0.27 per share was 4.5% above analysts’ consensus estimates.
Avantor's Q4 net sales missed estimates, but adjusted EPS beat expectations. The company projects 2025 organic revenue growth and stronger free cash flow.
Quantum-Si partners with NVIDIA to advance AI-powered proteomics, collaborates with Avantor for U.S. and Canada distribution of protein sequencing tech.
